查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球临床风险分组解决方案市场 - 2023-2030年
市场调查报告书
商品编码
1290354

全球临床风险分组解决方案市场 - 2023-2030年

Global Clinical Risk Grouping Solutions Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球临床风险分组解决方案的市场规模在2022年达到6.0431亿美元，预计到2030年将见证有利可图的增长，达到16.5883亿美元。在预测期间（2023-2030年），该市场的年复合增长率为13.9%。医疗保健的风险管理是一套复杂的系统、流程、程序和报告结构，旨在检测、监测、评估、减轻和预防病人的风险。

临床风险分组解决方案的市场受到以下因素的驱动：基于价值的护理、医疗成本上升、人口健康管理、数据分析和技术、监管和报销变化、改善护理协调以及以病人为中心的方法。

临床风险分组解决方案市场有几个制约因素，会影响其发展。这些因素包括成本和预算限制、对变革的抵制、分散的医疗系统、数据隐私和安全问题、有限的意识和培训，以及监管和法律挑战。

市场动态

对基于价值的护理的关注不断增加

基于价值的护理是一种强调在控制成本的同时提高病人疗效的模式。它将医疗系统的重点从收费服务方式转移到以价值为基础的护理，奖励质量、效率和病人满意度。

临床风险解决方案在识别和管理可能影响患者疗效的风险方面发挥了关键作用。这些解决方案帮助医疗机构监测质量指标，确定需要改进的领域，并实施战略以减少风险和加强病人安全。

它们还可以促进有效的护理协调和过渡，执行绩效测量和报告，成本控制和效率，以及人口健康管理。这些解决方案可以帮助医疗机构实施积极主动的战略，以防止不良事件的发生，减少再入院，并改善整体人口健康状况。

监管和法律挑战

医疗机构的临床风险解决方案面临各种监管和法律挑战，这是阻碍市场发展的主要因素。监管和法律方面的挑战，如数据隐私和安全、监管合规、标准化和互操作性。

数据隐私法规，如《一般数据保护条例》（GDPR）和《健康保险可携性和责任法案》（HIPAA），对于解决方案供应商来说，确保其系统符合这些法规是至关重要的。法规遵从要求医疗机构报告不良事件、事件管理和质量报告。

由于缺乏统一的数据格式、术语和通信协议，标准化和互操作性可能具有挑战性。解决方案供应商应努力实现互操作性标准，并与其他利益相关者合作，以确保临床风险解决方案和现有医疗IT基础设施之间的顺利整合和数据共享。

COVID-19影响分析

COVID-19大流行对临床风险分组解决方案市场产生了重大影响，人们更加关注病人安全，更多地采用远程医疗和远程监控服务，并增强了数据分析和监控能力。这导致了对能够帮助识别和减少与传染病和其他不良事件有关的风险的临床风险解决方案的更大需求。

远程医疗和远程监测服务也得到了扩展，具有强大数据分析能力的临床风险解决方案在跟踪和分析COVID-19相关数据方面发挥了作用，使医疗机构和公共卫生机构能够有效地应对这场危机。这场大流行需要监管方面的变化和增加医疗服务的灵活性。为确保安全，实施了远程工作政策和虚拟协作工具。

俄乌冲突分析

俄乌冲突对两国的临床风险分组解决方案市场产生了重大影响，包括医疗基础设施的中断、医疗专业人员的迁移、有限的财政资源、监管和法律挑战、数据交换和互操作性的中断，以及地缘政治不稳定导致的不确定市场环境。医疗机构和解决方案供应商可能需要驾驭不断变化的法规，并确保他们的解决方案与不断变化的环境相一致。战争也对这两个国家的临床试验产生了负面影响。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品抽查
  • 按部署情况分类
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 对以价值为基础的护理越来越重视
    • 限制因素
      • 监管和法律挑战
    • 机会
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按产品分类

  • 数据分析
  • 仪表板和数据可视化工具
  • 风险报告解决方案

第8章：按部署分类

  • 公共云
  • 私有云
  • 混合云

第九章：按终端用户分类

  • 医疗服务提供者
  • 临床研究机构
  • 制药和生物技术公司
  • 其他

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • 3M Company
    • 公司概述
    • 产品组合和说明
    • 财务概况
    • 主要发展情况
  • Optum Inc.
  • Conduent Inc.
  • Lightbeam Health Solutions
  • Health Catalyst
  • Change Healthcare
  • Milliman Inc.
  • COTIVITI Inc.
  • Episource
  • Med-IQ Inc

第十三章 ：附录

简介目录
Product Code: HCIT5267

Market Overview

The Global Clinical Risk Grouping Solutions Market size reached US$ 604.31 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,658.83 million by 2030. The market is exhibiting at a CAGR of 13.9% during the forecast period (2023-2030). Risk management in healthcare is a complex set of systems, processes, procedures, and reporting structures designed to detect, monitor, assess, mitigate, and prevent risks to patients.

The market for clinical risk grouping solutions is driven by factors such as value-based care, rising healthcare costs, population health management, data analytics and technology, regulatory and reimbursement changes, improved care coordination, and a patient-centric approach.

The clinical risk grouping solutions market has several restraints that can affect its development. These include cost and budgetary constraints, resistance to change, fragmented healthcare systems, data privacy and security concerns, limited awareness and training, and regulatory and legal challenges.

Market Dynamics

Rising Focus On Value-Based Care

Value-based care is a model that emphasizes improving patient outcomes while controlling costs. It shifts the healthcare system's focus from a fee-for-service approach to value-based care that rewards quality, efficiency, and patient satisfaction.

Clinical risk solutions play a crucial role in identifying and managing risks that could compromise patient outcomes. These solutions help healthcare organizations monitor quality metrics, identify areas for improvement, and implement strategies to mitigate risks and enhance patient safety.

They can also facilitate effective care coordination and transitions, perform performance measurement and reporting, cost containment and efficiency, and population health management. These solutions can help healthcare organizations implement proactive strategies to prevent adverse events, reduce hospital readmissions, and improve overall population health outcomes.

Regulatory and Legal Challenges

Clinical risk solutions in healthcare settings face a variety of regulatory and legal challenges, the main factor hampering the market. The regulatory and legal challenges such as data privacy and security, regulatory compliance, and standardization and interoperability.

Data privacy regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA) are essential for solution providers to ensure their systems comply with these regulations. Regulatory compliance requires healthcare organizations to report adverse events, incident management, and quality reporting.

Standardization and interoperability can be challenging due to a lack of uniform data formats, terminology, and communication protocols. Solution providers should work towards interoperability standards and collaborate with other stakeholders to ensure smooth integration and data sharing between clinical risk solutions and existing healthcare IT infrastructure.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical risk grouping solutions market, with the increased focus on patient safety, increased adoption of telehealth and remote monitoring services, and enhanced data analytics and surveillance capabilities. This has led to a greater demand for clinical risk solutions that can help identify and reduce risks associated with infectious diseases and other adverse events.

Telehealth and remote monitoring services have also been expanded, and clinical risk solutions with robust data analytics capabilities were instrumental in tracking and analyzing COVID-19-related data, enabling healthcare organizations and public health agencies to respond effectively to the crisis. The pandemic necessitated regulatory changes and increased flexibility in healthcare delivery. Remote work policies and virtual collaboration tools were implemented to ensure safety.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the clinical risk grouping solutions market in both countries including disruption of healthcare infrastructure, displacement of healthcare professionals, limited financial resources, regulatory and legal challenges, data exchange and interoperability disruption, and an uncertain market environment due to geopolitical instability. Healthcare organizations and solution providers may need to navigate evolving regulations and ensure their solutions align with the changing landscape. The war also negatively impacted the clinical trials in both countries.

Segment Analysis

The global clinical risk grouping solutions market is segmented based on product, deployment, end-user, and region.

Based on Product, Dashboard And Data Visualization Tools Segment is Expected To Dominate The Market Share

Based on the product, the dashboard and data visualization tools segment is expected to dominate the market share of 38.7% during the forecast period due to its ability to predict payment processes, payment risk, and ease of comprehension of clinical data. The demand for modern technologies such as big data and AI in the healthcare industry and increased initiatives to reduce the prices of healthcare services are expected to drive market expansion. In addition, rising chronic illness prevalence and increased use of cloud services in data management are likely to drive growth in the worldwide clinical risk grouping solutions market.

Geographical Analysis

North America Accounted for Approximately 40.2% of the Market Share in 2022 Due To Technologically Advanced Healthcare Infrastructure

North America holds the largest market share in the clinical risk grouping solutions market due to its technologically advanced healthcare infrastructure. Several factors contribute to North America's dominance in this market such as advanced healthcare systems, regulatory environment, financial resources, research and development, quality and patient safety, and emphasis on quality and patient safety.

These factors enable healthcare organizations in the region to readily adopt and implement clinical risk solutions to enhance patient safety and risk management. North American healthcare systems place a strong emphasis on quality improvement and patient safety in the clinical risk grouping solutions market.

Competitive Landscape

The major global players in the market include: 3M Company, Optum Inc., Conduent Inc., Lightbeam Health Solutions, Health Catalyst, Change Healthcare, Milliman Inc., COTIVITI Inc., Episource, and Med-IQ Inc.

Why Purchase the Report?

  • To visualize the global clinical risk grouping solutions market segmentation based on product, deployment, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical risk grouping solutions market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global clinical risk grouping solutions market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Deployment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising focus on value-based care
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory and legal challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Data Analytics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dashboard and Data Visualization Tools
  • 7.4. Risks Reporting Solutions

8. By Deployment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 8.1.2. Market Attractiveness Index, By Deployment
  • 8.2. Public Cloud*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Private Cloud
  • 8.4. Hybrid Cloud

9. By End-User

  • 9.1. Healthcare service providers
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Clinical Research Organizations
  • 9.3. Pharmaceutical and Biotech Firms
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. 3M Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Optum Inc.
  • 12.3. Conduent Inc.
  • 12.4. Lightbeam Health Solutions
  • 12.5. Health Catalyst
  • 12.6. Change Healthcare
  • 12.7. Milliman Inc.
  • 12.8. COTIVITI Inc.
  • 12.9. Episource
  • 12.10. Med-IQ Inc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us